Institutional members access full text with Ovid®

Share this article on:

Modulatory Role for CCK-B Antagonists in Parkinson's Disease.

Boyce, S.; Rupniak, N. M. J.; Tye, S.; Steventon, M. J.; Iversen, S. D.
Clinical Neuropharmacology: August 1990
Original Contributions: PDF Only

Summary: We examined the ability of selective CCK-A and CCK-B receptor antagonists to induce or modulate the locomotor stimulant effects of dopamine agonists in MFTP-treated squirrel monkeys. Administration of 1-100 [mu]g/kg i.p. of either the selective CCK-A receptor antagonist devazepide (MK-329) or the CCK-B receptor antagonist L-365,260 alone failed to stimulate a locomotor response in parkinsonian monkeys. In contrast, treatment with L-365,260 caused a 50-60% potentiation of the locomotor stimulatory effects of L-DOPA or (+)-PHNO. No such modulatory effects were observed following pretreatment with devazepide. We suggest that CCK-B receptor antagonists may be useful adjuncts to existing dopamine replacement therapy for improved management of Parkinson's disease.

(C) Williams & Wilkins 1990. All Rights Reserved.